Evidence map›Paper›PMID 25819778›Full record

ArticleThe lancet. Diabetes & endocrinology2015

A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys.

Kaveh Hajifathalian, Peter Ueda, Yuan Lu, Mark Woodward, Alireza Ahmadvand, Carlos A Aguilar-Salinas, Fereidoun Azizi, Renata Cifkova, Mariachiara Di Cesare, Louise Eriksen and 18 more

2 registry-linked trialsAbstract read
In one paragraph

Article in The lancet. Diabetes & endocrinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 152 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 13 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03696940 phase3unknown statusstarted 2018, after this paper: background citation

Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina

Ran2018Enrolled120Registered outcomes6Posted comparisons0ConditionsCardiovascular Risk Factor, DyslipidemiasArmsAtorvastatin 10mg, L-Carnitine 500Mg Oral Tablet + Atorvastatin 10 mg
Open the trial in the graph
NCT03512691 naunknown statusnot on this mapstarted 2018, after this paper: background citation

The Nueva Ecija Cardiovascular Risk Experiment: An Evaluation of the Impact of Risk Information and Screening on Primary Prevention of Cardiovascular Disease

TypeinterventionalSponsorUPecon Foundation, Inc.Ran2018 to 2021Enrolled5,019ConditionsCardiovascular Diseases, Cardiovascular Risk FactorArmsInformation on CVD Risk, Lottery Incentive
3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 13 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Risk scores for type 2 diabetes mellitus in Latin America: a systematic review of population-based studies.Diabetic medicine : a journal of the British Diabetic Association · 2019
    Pooled it
  7. 2018 Guidelines for the management of dyslipidemia.The Korean journal of internal medicine · 2019
    Guideline
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Risk scoring for the primary prevention of cardiovascular disease.The Cochrane database of systematic reviews · 2017
    Pooled it
  12. Guideline
  13. Pooled it
  14. Trial
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors.

Kaveh HajifathalianDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA, USA; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Peter UedaDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA, USA.
Yuan LuDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA, USA.
Mark WoodwardThe George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, UK; The George Institute for Global Health, University of Sydney, Sydney, NSW, Australia; Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
Alireza AhmadvandMRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK; Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Carlos A Aguilar-SalinasDepartment of Endocrinology and Metabolism, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico.
Fereidoun AziziResearch Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Renata CifkovaDepartment of Preventive Cardiology, Thomayer Teaching Hospital, Prague, Czech Republic.
Mariachiara Di CesareMRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Louise EriksenNational Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark.
Farshad FarzadfarNon-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Nayu IkedaCenter for International Collaboration and Partnership, National Institute of Health and Nutrition, Tokyo, Japan.
Davood KhaliliResearch Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Young-Ho KhangInstitute of Health Policy and Management, Seoul National University College of Medicine, Seoul, South Korea.
Vera LanskaStatistical Unit, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Luz León-MuñozDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/Idipaz, Madrid, Spain; CIBER of Epidemiology and Public Health, Madrid, Spain.
Dianna MaglianoBaker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
Kelias P MsyambozaWHO, Malawi Country Office, Lilongwe, Malawi.
Kyungwon OhDivision of Health and Nutrition Survey, Korea Centers for Disease Control and Prevention, Cheongwon-gun, South Korea.
Fernando Rodríguez-ArtalejoDepartment of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/Idipaz, Madrid, Spain; CIBER of Epidemiology and Public Health, Madrid, Spain.
Rosalba Rojas-MartinezCentro de Investigación en Salud Poblacional, Instituto Nacional de Salud Publica, Mexico City, Mexico.
Jonathan E ShawBaker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
Gretchen A StevensDepartment of Health Statistics and Information Systems, WHO, Geneva, Switzerland.
Janne TolstrupDepartment of Preventive Cardiology, Thomayer Teaching Hospital, Prague, Czech Republic.
Bin ZhouMRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Joshua A SalomonDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA, USA.
Majid EzzatiMRC-PHE Centre for Environment and Health, Imperial College London, London, UK; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Goodarz DanaeiDepartment of Global Health and Population, Harvard School of Public Health, Boston, MA, USA; Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA. Electronic address: gdanaei@hsph.harvard.edu.

Funding

UNIV OF NORTH CAROLINA CLINICAL NUTRITION RESEARCH UNITP30DK056350 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SUSAN M. SMITH · 1999 to 2026
$31.6M
MONITORING SOCIAL CHANGE: HEALTH, REPRODUCTION, AGINGR01HD030880 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ADAIR, LINDA S, POPKIN, BARRY M · 1994 to 2024
$27.0M
Carolina Population CenterR24HD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MORGAN, SAMUEL PHILIP · 2005 to 2014
$10.0M
Reducing disparities in diabetes through expanded insurance coverage.R01DK090435 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI DANAEI, GOODARZ · 2011 to 2014
$1.8M
CHILD HEALTH EFFECTS OF RAPID SOCIO-DEMOGRAPHIC CHANGER01HD038700 · NICHD · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI POPKIN, BARRY M · 2000 to 2004
$1.5M
Medical Research CouncilNICHD NIH HHS 5 R24 HD050924NICHD NIH HHS R01 HD030880NICHD NIH HHS R01 HD038700NICHD NIH HHS R01-HD30880NICHD NIH HHS R01-HD38700NICHD NIH HHS R24 HD050924NIDDK NIH HHS 1R01-DK090435NIDDK NIH HHS DK056350NIDDK NIH HHS P30 DK056350NIDDK NIH HHS R01 DK090435Wellcome Trust 100693Wellcome Trust 101506World Health Organization 001
6 · The paper itself

Abstract

backgroundTreatment of cardiovascular risk factors based on disease risk depends on valid risk prediction equations. We aimed to develop, and apply in example countries, a risk prediction equation for cardiovascular disease (consisting here of coronary heart disease and stroke) that can be recalibrated and updated for application in different countries with routinely available information.

methodsWe used data from eight prospective cohort studies to estimate coefficients of the risk equation with proportional hazard regressions. The risk prediction equation included smoking, blood pressure, diabetes, and total cholesterol, and allowed the effects of sex and age on cardiovascular disease to vary between cohorts or countries. We developed risk equations for fatal cardiovascular disease and for fatal plus non-fatal cardiovascular disease. We validated the risk equations internally and also using data from three cohorts that were not used to create the equations. We then used the risk prediction equation and data from recent (2006 or later) national health surveys to estimate the proportion of the population at different levels of cardiovascular disease risk in 11 countries from different world regions (China, Czech Republic, Denmark, England, Iran, Japan, Malawi, Mexico, South Korea, Spain, and USA).

findingsThe risk score discriminated well in internal and external validations, with C statistics generally 70% or more. At any age and risk factor level, the estimated 10 year fatal cardiovascular disease risk varied substantially between countries. The prevalence of people at high risk of fatal cardiovascular disease was lowest in South Korea, Spain, and Denmark, where only 5-10% of men and women had more than a 10% risk, and 62-77% of men and 79-82% of women had less than a 3% risk. Conversely, the proportion of people at high risk of fatal cardiovascular disease was largest in China and Mexico. In China, 33% of men and 28% of women had a 10-year risk of fatal cardiovascular disease of 10% or more, whereas in Mexico, the prevalence of this high risk was 16% for men and 11% for women. The prevalence of less than a 3% risk was 37% for men and 42% for women in China, and 55% for men and 69% for women in Mexico.

interpretationWe developed a cardiovascular disease risk equation that can be recalibrated for application in different countries with routinely available information. The estimated percentage of people at high risk of fatal cardiovascular disease was higher in low-income and middle-income countries than in high-income countries.

fundingUS National Institutes of Health, UK Medical Research Council, Wellcome Trust.

Indexed as

AdultAgedCalibrationCardiovascular DiseasesCoronary DiseaseDiagnostic Techniques, CardiovascularFemaleHealth Status IndicatorsHumansMaleMiddle AgedProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsStroke

Identifiers

PMID25819778
PMCPMC7615120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.